Praxis Precision Medicine, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 6, 2026, covering the quarterly period ended June 30, 2026.

Key Highlights

  • Share count: As of July 31, 2026, the company had 27,919,988 shares of common stock outstanding, with a par value of $0.0001 per share.
  • Exchange listing: Common stock trades on The Nasdaq Global Select Market under the ticker symbol PRAX.
  • Filer status: The company is classified as a large accelerated filer, and is not a smaller reporting company or emerging growth company.
  • Shell company status: The registrant confirmed it is not a shell company as defined under Rule 12b-2 of the Exchange Act.
  • Forward-looking statements: The filing includes forward-looking statements subject to the company's cautionary language, covering topics such as regulatory submissions, clinical trial timing, and funding of operations.

Praxis Precision Medicines Reports Second Quarter 2026 Operating Position

Praxis Precision Medicines, Inc., a Delaware-incorporated clinical-stage biopharmaceutical company focused on precision medicines and product candidates, filed its Form 10-Q for the quarter ended June 30, 2026. The company is headquartered at 99 High Street, 30th Floor, Boston, MA 02110, and is registered with Commission File Number 001-39620. The filing covers condensed consolidated financial statements for the three and six months ended June 30, 2026 and 2025, including balance sheets, statements of operations, and cash flows, all presented on an unaudited basis.

According to the filing, the company confirmed compliance with SEC periodic reporting requirements, having filed all required reports during the preceding 12 months and being subject to filing requirements for the past 90 days. The registrant also confirmed timely electronic submission of all required Interactive Data Files under Rule 405 of Regulation S-T. The filing's Management Discussion and Analysis section, covering pages 19 through 29, addresses results of operations and financial condition, while Item 3 provides quantitative and qualitative disclosures about market risk.

The filing notes that forward-looking statements contained in the report are the company's own and are subject to its cautionary language. These statements, according to the filing, relate to future events including "potential regulatory submissions, progress or approvals," the "success, cost and timing of our product candidate development activities and clinical trials," and "our ability to fund our operations and obtain additional funding." The company stated it has "no current intention" of updating these statements except as required by applicable law.

What Was Disclosed

Praxis Precision Medicines submitted its quarterly report for the period ended June 30, 2026, reporting 27,919,988 shares outstanding as of July 31, 2026, large accelerated filer status, and listing on The Nasdaq Global Select Market under symbol PRAX.